Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict lung damage from CAR t-cell therapy?

NCT ID NCT07794423

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study looks back at the medical records of about 266 adults who received CAR T-cell therapy for blood cancers. The goal is to describe lung complications that happen within 30 days or up to 2 years after treatment. Researchers will also look for patient characteristics that might predict these complications. The findings could help doctors improve follow-up care and prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No intervention for the patient, study on medical records
What this could lead to
If this study succeeds, it could help doctors predict and prevent lung problems in people receiving CAR T-cell therapy.
What could go wrong
This is a retrospective review of past records, so it cannot prove cause and effect. The findings may not apply to all patients or future treatment practices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

266 people

The number who actually took part.

Started

Dec 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

To be included in the study, patients must meet all of the following criteria: * Be an adult (Majeur). * Have received CAR T-cell based therapy. * Received this therapy at the Hematology department of Lyon Sud (CHLS). * Have a minimum of 2 years of follow-up data available at the time of the data collection start date.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Be an adult (Majeur). * Have received CAR T-cell based therapy. * Received this therapy at the Hematology department of Lyon Sud (CHLS). * Have a minimum of 2 years of follow-up data available at the time of the data collection start date. Exclusion Criteria: * none

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Car-T cells are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Car-T cells Pulmonary complications

Contacts and locations

Locations

  • Centre hospitalier Lyon Sud

    Pierre-Bénite, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.